Optimal time to treat migraine pain with Relpax; is early in the attack, new s...( New York (June 11 2004) Treating a mi...),Health

New York (June 11, 2004) Treating a migraine attack early with Relpax (eletriptan HBr) provides greater efficacy for migraine sufferers than waiting until the pain becomes more intense, according to a new study. In the study, two-hour and sustained pain-free rates nearly doubled among patients who treated their attack while the pain was still mild compared with those who waited until the pain became moderate to severe.

The results were presented today at the 46th American Headache Society annual meeting.

"Patients too often will delay taking prescription medication, believing the pain will go away, which is not the optimal way to treat migraines," said Dr. Jan Brandes, clinical instructor in the department of neurology at Vanderbilt University School of Medicine and a neurologist at the Nashville Neuroscience Group. "This study provides new evidence that migraine sufferers should treat at the first signs of an attack, and clearly demonstrates the effectiveness of Relpax in treating migraine, especially when taken early during the mild pain phase."

Overall, migraine patients taking Relpax 40 mg, the recommended daily dose, experienced significantly higher two-hour pain-free rates than those taking placebo (47 percent vs. 22 percent). Among patients who waited to take Relpax 40 mg until the attack became moderate to severe, two-hour pain-free rates were 39 percent (compared with 21 percent taking placebo). However, among the 25 percent of patients who treated their attack with Relpax 40 mg when the pain was still mild, two-hour pain-free rates jumped to 68 percent (compared with 25 percent taking placebo). The highest two-hour pain-free rates were seen among patients with mild pain taking Relpax 40 mg within 30 minutes of pain onset (71 percent vs. 23 percent on placebo). In addition, sustained pain-free rates were higher for patients who treated with Relpax 40 mg when the pain was mild (56 percent) compared with those treating when t
'"/>

Contact: Alison Lehanski
alison.lehanski@pfizer.com
212-733-8087
Marina Maher Communications
11-Jun-2004

Page: 1 2
Related medicine news :

1. Optimal treatment of carpal tunnel syndrome
2. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
3. Hormonal treatment improves survival in high-risk prostate cancer patients
4. Chronic pain treatments more effective when taken together, new study shows
5. Brain activity prior to treatment flags vulnerability to antidepressant side effects
6. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
7. OHSU scientists test medication to treat involuntary weight loss
8. Cultural and social factors influence prostate cancer treatment
9. Research offers hope of new treatments for liver damage
10. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
11. Risky surgery not always necessary to treat cervical disease